CytomX Therapeutics (NASDAQ:CTMX) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a research note published on Tuesday morning,Benzinga reports.

CytomX Therapeutics Price Performance

Shares of NASDAQ CTMX opened at $1.02 on Tuesday. CytomX Therapeutics has a 1 year low of $0.83 and a 1 year high of $5.85. The company’s 50-day moving average is $1.06 and its 200 day moving average is $1.17. The stock has a market capitalization of $79.82 million, a P/E ratio of 6.00 and a beta of 1.03.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. The firm had revenue of $33.43 million for the quarter, compared to the consensus estimate of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same quarter in the prior year, the business earned $0.04 EPS. Research analysts anticipate that CytomX Therapeutics will post -0.05 earnings per share for the current year.

Institutional Trading of CytomX Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Candriam S.C.A. purchased a new position in CytomX Therapeutics during the 2nd quarter valued at about $256,000. Acadian Asset Management LLC boosted its position in shares of CytomX Therapeutics by 1.4% in the 2nd quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock worth $3,324,000 after purchasing an additional 37,739 shares in the last quarter. XTX Topco Ltd grew its stake in shares of CytomX Therapeutics by 382.6% in the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after buying an additional 48,033 shares during the last quarter. Sei Investments Co. bought a new position in CytomX Therapeutics during the 2nd quarter valued at approximately $467,000. Finally, Cubist Systematic Strategies LLC increased its position in CytomX Therapeutics by 96.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 40,309 shares in the last quarter. 67.77% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.